drugset
drugset / Trial / NCT04630444

Riluzole Effects on Hippocampus Biomarkers

NCT04630444 ↗

Phase 0 Completed 20 enrolled Mclean Hospital Brain & Behavior Research Foundation · collab
NaSingle-groupOpen-labelBasic science

Summary

To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS.

Timeline

Start
2017-03-16
Primary completion
2019-03-16
Completion
2019-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Riluzole Small molecule 50 mg —

Indications

post-traumatic stress disorder